Idelalisib

Adelanib is a targeted therapy drug for chronic lymphocytic leukemia (CLL) and other types of lymphoma. It belongs to the PI3K inhibitor category, especially a highly selective inhibitor of the PI3Kδ isoform.

1. Drug name

1. Generic name: Idelalisib;

2. Trade name: Zydelig®.

2. Indications

1. Relapsed chronic lymphocytic leukemia (CLL): Combined with rituximab, it is suitable for patients who are only suitable for rituximab monotherapy due to comorbidities.

2. Relapsed follicular B-cell non-Hodgkin lymphoma (FL): Applicable to patients who have received at least two systemic therapies.

3. Relapsed small lymphocytic lymphoma (SLL): Applicable to patients who have received at least two systemic therapies.

3. Specifications and properties

1. Specifications: 150mg

2. Properties: Tablets

4. Main ingredients

Active ingredient: Idelalisib, a PI3Kδ kinase inhibitor.

5. Usage and dosage

1. Recommended dose: 150 mg orally, twice a day.

2. How to take the medicine: Swallow the whole tablet before or after meals.

3. Treatment of missed doses: If the missed dose is <6 hours, take it immediately; if it is >6 hours, skip it and take it at the original time next time.

6. Dose adjustment

The dose of needs to be adjusted according to toxic reactions:

1. Hepatotoxicity: Pause when 5 times the upper limit of ALT/AST>, and reduce the dose to 100mg after recovery.

2. Diarrhea: Severe diarrhea requires suspension or reduction.

3. Neutropenia: Pause when ANC<0.5Gi/L.

7. Medication precautions

1. Monitoring requirements: Check liver function and blood routine regularly during treatment.

2. Diet: No special requirements.

3. Vomiting: If you vomit after taking the medicine, there is no need to take a supplement. Take the next dose as planned.

8. Medication for special groups

1. Pregnant women: Contraindicated as it may cause fetal malformations.

2. Lactation period: Discontinue medication or stop breastfeeding.

3. Liver injury: Use with caution in those whose baseline ALT/AST is >2.5 times the upper limit.

9. Adverse reactions

1. Common (≥20%): Diarrhea, fever, fatigue, cough, pneumonia, etc.

2. Serious reactions: Hepatotoxicity, intestinal perforation, pneumonia, etc.

10. Contraindications

It is contraindicated in patients with severe allergies to adranid (such as toxic epidermal necrolysis).

11. Drug interactions

1. Avoid combined use of strong CYP3A inducers (such as rifampicin).

2. Avoid combined use of CYP3A substrates (such as midazolam).

12. Storage method

1. Storage temperature: 20-30°C (68-86°F).

2. Keep the original packaging and keep it sealed.